Prader-Willi syndrome
Information
- Disease name
- Prader-Willi syndrome
- Disease ID
- DOID:11983
- Description
- "A chromosomal disease that is characterized by weak muscle tone, feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating and obesity." [url:https\://ghr.nlm.nih.gov/condition/prader-willi-syndrome, url:https\://www.ncbi.nlm.nih.gov/books/NBK1330/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03848481 | Active, not recruiting | Phase 2 | CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) | November 23, 2020 | October 2024 |
| NCT05701774 | Active, not recruiting | Phase 3 | Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome | January 31, 2023 | June 2028 |
| NCT04257929 | Active, not recruiting | Phase 2 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension | December 9, 2020 | September 7, 2028 |
| NCT00375089 | Completed | Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity | September 2006 | January 2014 | |
| NCT00444964 | Completed | Phase 3 | Growth Hormone Use in Adults With Prader-Willi Syndrome | April 2005 | January 1, 2012 |
| NCT00551343 | Completed | N/A | Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome | October 2007 | September 2008 |
| NCT00705172 | Completed | Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome | November 2008 | November 2008 | |
| NCT00800852 | Completed | Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome | |||
| NCT02205450 | Completed | Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell | September 2014 | July 29, 2019 | |
| NCT00065923 | Completed | N/A | Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome | July 2002 | |
| NCT00372125 | Completed | N/A | Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome | April 2005 | March 2010 |
| NCT00932932 | Completed | Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls | February 2009 | August 2010 | |
| NCT01298180 | Completed | Phase 4 | Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? | January 2009 | May 2013 |
| NCT01401244 | Completed | Phase 1 | Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers | July 14, 2011 | September 27, 2011 |
| NCT01444898 | Completed | N/A | Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome | March 2012 | December 2013 |
| NCT01479322 | Completed | Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome | January 2007 | July 2007 | |
| NCT01523288 | Completed | The Intestinal Function in People With Prader-Willi Syndrome | February 2011 | January 2012 | |
| NCT01548521 | Completed | Phase 1/Phase 2 | Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies | July 2011 | April 2012 |
| NCT01622751 | Completed | Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome | January 2007 | June 2007 | |
| NCT01818921 | Completed | Phase 2 | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome | June 2013 | November 2013 |
| NCT01863017 | Completed | N/A | Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome | April 2013 | October 6, 2016 |
| NCT02034071 | Completed | Phase 1/Phase 2 | Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome | April 2014 | May 2015 |
| NCT02204163 | Completed | Phase 3 | Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome | June 2014 | December 2017 |
| NCT00004351 | Completed | Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes | September 1999 | ||
| NCT02311673 | Completed | Phase 2 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | March 19, 2015 | October 26, 2016 |
| NCT02381457 | Completed | SNP-based Microdeletion and Aneuploidy RegisTry (SMART) | April 2015 | June 2020 | |
| NCT02529085 | Completed | N/A | PWS European Blood Bank for Infants and Controls From 0 to 48 Months | March 2013 | June 1, 2017 |
| NCT02629991 | Completed | Phase 2 | Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome | October 2015 | May 2018 |
| NCT02670694 | Completed | Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW | June 2011 | July 2013 | |
| NCT02804373 | Completed | Phase 2/Phase 3 | Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome | June 2014 | June 18, 2019 |
| NCT03081832 | Completed | N/A | Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants. | January 2017 | December 2018 |
| NCT03114371 | Completed | N/A | Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years | November 28, 2016 | January 11, 2019 |
| NCT03245762 | Completed | Phase 1/Phase 2 | Intranasal Oxytocin for Infants With Prader-Willi Syndrome | August 1, 2017 | January 4, 2018 |
| NCT03274856 | Completed | Phase 2 | A Study of GLWL-01 in Patients With Prader-Willi Syndrome | February 20, 2018 | June 12, 2019 |
| NCT03440814 | Completed | Phase 3 | A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome | May 9, 2018 | May 1, 2020 |
| NCT03548480 | Completed | N/A | Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment | January 1, 2018 | January 31, 2019 |
| NCT03565081 | Completed | N/A | Effects of Progressive Elastic Band Resistance Training | February 1, 2016 | December 31, 2016 |
| NCT03616509 | Completed | Phase 4 | GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition | June 19, 2017 | July 26, 2019 |
| NCT03649477 | Completed | Phase 3 | Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome | November 20, 2018 | July 9, 2022 |
| NCT03689621 | Completed | N/A | Proof of Concept Study of Vagus Nerve Stimulation | January 1, 2016 | December 31, 2018 |
| NCT03714373 | Completed | Phase 3 | Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period | October 1, 2018 | August 17, 2023 |
| NCT03718416 | Completed | Natural History Study of Serious Medical Events in PWS | September 28, 2018 | January 31, 2024 | |
| NCT04150991 | Completed | N/A | Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome | July 1, 2019 | February 22, 2023 |
| NCT04283578 | Completed | Phase 3 | Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome | March 10, 2020 | March 14, 2022 |
| NCT04526379 | Completed | N/A | Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation | September 7, 2020 | April 27, 2022 |
| NCT04685057 | Completed | N/A | Probiotic Treatment for Prader-Willi Syndrome | January 11, 2021 | June 30, 2022 |
| NCT04697381 | Completed | Phase 3 | Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS | February 9, 2021 | April 15, 2024 |
| NCT04700644 | Completed | Assessment of CAI in Adults With PWS. | May 15, 2020 | June 6, 2020 | |
| NCT05298085 | Completed | Phase 2/Phase 3 | Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome | April 5, 2022 | April 11, 2023 |
| NCT05322096 | Completed | Phase 2 | Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | September 22, 2022 | April 10, 2024 |
| NCT05504395 | Completed | Phase 1 | A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome | November 14, 2022 | February 21, 2023 |
| NCT05541003 | Completed | Phase 2 | Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome | January 6, 2023 | May 30, 2023 |
| NCT05761184 | Completed | Characterization of Serum Proteome in Subjects With Prader Willi Syndrome (PROTEOMARKER) | April 28, 2022 | October 28, 2022 | |
| NCT05783791 | Completed | Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome | April 20, 2023 | July 21, 2023 | |
| NCT03836300 | Enrolling by invitation | N/A | Parent and Infant Inter(X)Action Intervention (PIXI) | November 30, 2018 | June 30, 2025 |
| NCT03655223 | Enrolling by invitation | Early Check: Expanded Screening in Newborns | October 15, 2018 | December 31, 2025 | |
| NCT06279052 | Not yet recruiting | N/A | Adolescent Projections During Transition in Prader-Willi Syndrome | March 1, 2024 | December 1, 2024 |
| NCT04484051 | Not yet recruiting | Growth Hormone Study in Adults With Prader-Willi Syndrome | March 24, 2023 | October 1, 2026 | |
| NCT06295315 | Recruiting | Evaluation of the Psychological Profile of Adult Patients With Prader-Willi Syndrome | April 21, 2023 | December 31, 2024 | |
| NCT05657860 | Recruiting | Phase 4 | Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome | December 17, 2020 | January 18, 2024 |
| NCT06366464 | Recruiting | Phase 3 | A Study of Pitolisant in Patients With Prader-Willi Syndrome | April 30, 2024 | July 2027 |
| NCT04032639 | Recruiting | Stress and Brain Response Using MEG in PWS | May 30, 2019 | May 2024 | |
| NCT05778032 | Recruiting | Biological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS) | May 25, 2022 | December 31, 2023 | |
| NCT06448871 | Recruiting | Ultrasound to Assess Sarcopenia in Prader Willi Syndrome | October 17, 2022 | June 30, 2024 | |
| NCT04463316 | Recruiting | GROWing Up With Rare GENEtic Syndromes | October 1, 2018 | January 1, 2030 | |
| NCT05791604 | Recruiting | N/A | The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics | April 1, 2023 | July 31, 2026 |
| NCT05938543 | Recruiting | N/A | Cerebellar TMS and Satiety in Prader-Willi Syndrome | September 1, 2023 | August 2025 |
| NCT05939453 | Recruiting | N/A | Impact of Bright Light Therapy on Prader-Willi Syndrome | October 1, 2023 | June 2025 |
| NCT04768803 | Recruiting | Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity | June 10, 2021 | December 15, 2023 | |
| NCT05032326 | Recruiting | Phase 3 | Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial | September 7, 2021 | April 1, 2025 |
| NCT02829684 | Recruiting | Register of Patients With Prader-Willi Syndrome | March 2009 | December 2026 | |
| NCT03031626 | Recruiting | Phase 4 | Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome | September 1, 2016 | December 15, 2024 |
| NCT05153434 | Recruiting | Phase 2 | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | May 27, 2022 | March 1, 2024 |
| NCT03197662 | Recruiting | Phase 2 | Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome | April 11, 2018 | August 31, 2023 |
| NCT05249998 | Recruiting | N/A | Improving Care of Prader-Willi Syndrome : Evaluation of a New Care Program Combining Adapted Physical Activity, Nutrition and Therapeutic Education | November 6, 2021 | April 2024 |
| NCT05945576 | Recruiting | IDMet (RaDiCo Cohort) (RaDiCo-IDMet) | March 10, 2017 | March 10, 2032 | |
| NCT06144645 | Recruiting | Phase 3 | A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | January 8, 2024 | December 1, 2027 |
| NCT05879614 | Suspended | Phase 2 | An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) | September 1, 2023 | June 30, 2024 |
| NCT03101826 | Terminated | N/A | Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory | November 1, 2017 | March 8, 2023 |
| NCT03871751 | Terminated | N/A | Home-based SSP on Individuals With PWS | April 8, 2019 | December 16, 2019 |
| NCT02179151 | Terminated | Phase 3 | Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome | September 2014 | October 2016 |
| NCT05098509 | Terminated | Phase 2/Phase 3 | A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome | April 13, 2022 | October 31, 2022 |
| NCT00399893 | Terminated | N/A | Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS) | December 2006 | September 2010 |
| NCT02810483 | Terminated | Phase 3 | Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks | December 2012 | June 2016 |
| NCT03458416 | Terminated | Phase 2 | A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome | September 6, 2018 | July 31, 2019 |
| NCT03790865 | Terminated | Phase 2/Phase 3 | Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome | March 25, 2019 | May 25, 2020 |
| NCT02844933 | Terminated | Phase 2 | Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome | May 9, 2018 | July 31, 2019 |
| NCT00603109 | Terminated | Phase 3 | Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome | August 2007 | January 2009 |
| NCT00175305 | Terminated | Phase 3 | Prader-Willi Syndrome and Appetite | August 2004 | October 2007 |
| NCT02263781 | Unknown status | N/A | PREPL in Health and Disease | October 2014 | January 2015 |
| NCT02297022 | Unknown status | Phase 1 | Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome | October 2014 | October 2016 |
| NCT03554031 | Unknown status | Phase 3 | A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome | April 14, 2018 | January 1, 2020 |
| NCT03324906 | Unknown status | N/A | Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome | May 8, 2017 | November 2019 |
| NCT00808548 | Unknown status | Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome | December 2008 | December 2009 | |
| NCT03858023 | Unknown status | N/A | Therapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome | August 2016 | December 2019 |
| NCT02893618 | Unknown status | Phase 2 | A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) | July 2017 | December 2017 |
| NCT01520467 | Unknown status | N/A | Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome | April 2012 | October 2016 |
| NCT04102839 | Unknown status | PWS Outcomes Assessment Study | July 15, 2019 | March 31, 2021 | |
| NCT04086810 | Withdrawn | Phase 3 | An Open-Label Study of DCCR Tablet in Patients With PWS | October 2019 | October 2019 |
| NCT04066088 | Withdrawn | Phase 4 | Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome | December 1, 2019 | August 21, 2020 |
| NCT04396470 | Withdrawn | Phase 1/Phase 2 | tVNS in Children With Prader-Willi Syndrome | July 2020 | July 2021 |
| NCT05387798 | Withdrawn | Phase 3 | A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | January 2023 | August 2025 |
| NCT05198362 | Withdrawn | Phase 2 | Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome | December 28, 2021 | December 9, 2022 |
| NCT03831425 | Withdrawn | Phase 2 | Mitochondrial Complex I Dysfunction in PWS | June 1, 2023 | June 2024 |
- Disase is a (Disease Ontology)
- DOID:0080014
- Cross Reference ID (Disease Ontology)
- GARD:5575
- Cross Reference ID (Disease Ontology)
- ICD10CM:Q87.11
- Cross Reference ID (Disease Ontology)
- ICD9CM:759.81
- Cross Reference ID (Disease Ontology)
- MESH:D011218
- Cross Reference ID (Disease Ontology)
- MIM:176270
- Cross Reference ID (Disease Ontology)
- NCI:C75463
- Cross Reference ID (Disease Ontology)
- ORDO:739
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:205794007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0032897
- Exact Synonym (Disease Ontology)
- Prader Willi syndrome
- OrphaNumber from OrphaNet (Orphanet)
- 739
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011218